Pharmanutra S.p.a.MIL: PHN

04/06/2026 - Pharmanutra joins the euronext tech leaders segment

· Issued by Pharmanutra S.p.a.
PHARMANUTRA JOINS THE EURONEXT TECH LEADERS SEGMENT A PRESTIGIOUS RECOGNITION OF ITS SCIENTIFIC VOCATION AND ITS CAPACITY TO DEVELOP CUTTING-EDGE TECNOLOGIES IN THE NUTRACEUTICAL BUSINESS

Pisa, 4 June 2026 - Pharmanutra (MTA; Ticker PHN), a company specialising in mineral-based nutritional supplements and medical devises for muscles and joints, is pleased to announce its admission to the Euronext Tech Leaders segment, an initiative developed by Euronext to support the most innovative companies in the European technology landscape.

Following the annual review of the Euronext Tech Leaders segment, 12 new European companies were included into the prestigious group, thanks to their powerful drive for innovation in the technological field, along with a strong growth. Pharmanutra stands out for being the only Italian firm among the new entries and the sole enterprise in the nutraceutical business.

Andrea Lacorte, Chairman of Pharmanutra commented: "The entry into the Euronext Tech Leaders segment represents an important recognition of the value of innovation that has always characterized Pharmanutra, and a validation of the importance of believing in technological superiority. Being the only Italian company among the new entrants and the sole enterprise in the nutraceutical sector confirms the strength of our growth model and our ability to generate innovation by combining scientific research, proprietary technologies and international expansion. A milestone that enhances our visibility within the financial community and encourages us to continue along our development path." Roberto Lacorte, Vice Chairman and CEO of Pharmanutra commented: "The admission to the Euronext Tech Leaders segment represents a further significant step forward in our journey as a listed company. It is an important recognition of our ability to develop innovative and cutting-edge technologies-a vocation that has always been at the core of Pharmanutra's DNA and in which we continue to invest with strong conviction. Being part of this segment means increasing our international visibility and strengthening our attractiveness to a community of investors that is increasingly focused on companies whose growth is driven by technological innovation and the creation of sustainable value. We are particularly proud to join a network of excellence that helps reinforce Europe's competitiveness in the global technology landscape, and we would like to thank Euronext for the constant support it provides to companies engaged in growth and innovation paths."

The Euronext Tech Leaders Index, which Pharmanutra will join, will be updated after market close on Friday June 19, 2026 with effect from June 22, 2026.

Pharmanutra S.p.A.

Founded in 2003 in Pisa by Andrea and Roberto Lacorte, Pharmanutra is the holding company of an international Group engaged in the research, development, and commercialization of nutritional supplements, medical devices, and patented raw materials. A leader in iron-based supplements through its Sucrosomial® Technology (SiderAL® and Apportal®), and an emerging player in medical devices for mobility (Cetilar®), the Group internally manages the entire value chain and holds a solid portfolio of patents, brands, and clinical evidence.

Pharmanutra operates in over 80 countries, with subsidiaries in the USA and Spain, and also includes Akern S.r.l. (bioimpedance analysis) and Athletica Cetilar S.r.l. (sports medicine)

pharmanutragroup.com pharmanutra.it

For further information:

Pharmanutra S.p.A.

Via Campodavela 1 - 56122 Pisa

Tel. +39 050 7846500

Simona Del Re s.delre@pharmanutra.it investorrelation@pharmanutra.it Internal Press Office press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milano Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Earlier from Pharmanutra

All Pharmanutra news releases